Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

25.00 +0.16 (+0.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna’s BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union
Via ACCESSWIRE
Harpoon Therapeutics Remains Volatile After Promising News
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. 
Via MarketBeat
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Via ACCESSWIRE
Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age
Via ACCESSWIRE
Brad Miller Joins Moderna as Chief Information Officer
Via ACCESSWIRE
Moderna to Present at the Piper Sandler 34th Annual Healthcare Conference
Via ACCESSWIRE
Moderna Shares Environmental, Social and Governance Highlights at First ESG Day
Via ACCESSWIRE
Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster
Via ACCESSWIRE
Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates
Via ACCESSWIRE
David Jiménez Joins Moderna As U.S. General Manager
Via ACCESSWIRE
Moderna Tops BioSpace's Best Places to Work Ranking for Second Consecutive Year
Via ACCESSWIRE
While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants
EQNX::TICKER_START (OTCQB:BIXT),(NASDAQ:NVAX),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:INO),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial
Via ACCESSWIRE
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age
Via ACCESSWIRE
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
Learn more about Organicell Regenerative Medicine, Inc.from this latest report. 
Via TheNewswire.com
Moderna to Present at the Jefferies 2022 London Healthcare Conference
Via ACCESSWIRE
Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222
Via ACCESSWIRE
Why Investors Are Suddenly Excited About Vaxcyte
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet. 
Via MarketBeat
Moderna to Host First Environmental, Social and Governance (ESG) Day on November 10, 2022
Via ACCESSWIRE
Moderna Named a Top Employer by Science for Eighth Consecutive Year
Via ACCESSWIRE
Moderna Stock Went Up Because It Is Joining Hands With the US to Make Shots to Fight Ebola and Other Threats
Moderna Stock (NASDAQ:MRNA) On Wednesday, Moderna stock (NASDAQ:MRNA) increased after Bloomberg reported that the business and the United States Department of Defense is close to inking an agreement to... 
Via PressReach
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union
Via ACCESSWIRE
EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union
Via ACCESSWIRE
90-Day Analysis Shows Moderna’s Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster
Via ACCESSWIRE
Merck Nears Breakout Point After October Surprise Good News
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments. 
Via MarketBeat
Topics Stocks
Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries
Via ACCESSWIRE
Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022
Via ACCESSWIRE
Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine
Via ACCESSWIRE
Moderna exercises option to license proprietary targeting technology from Autolus
From Autolus Therapeutics plc
Via GlobeNewswire
Is Pfizer Stock Still Worth Buying After the Pandemic?
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations. 
Via MarketBeat
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.